Patients with ER + HER2- invasive breast cancer received chemotherapy in 74% of cases, compared to 90.0% of TNBC and 91.7% of HER2 + invasive breast cancers (p = 0.006). This evidence concerns the gene ERBB2 and invasive breast carcinoma.